Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
|Articles|August 1, 2002
Prevention best measure with post-inflammatory hyperpigmentation
New York - Dermatologists need to be particularly vigilant for post-inflammatory hyperpigmentation when treating patients of African descent or any other darker-skinned patient for dermatologic conditions that have an inflammatory component, Susan C. Taylor, M.D., said at the annual meetinig of The Skin of Color Center, St. Luke's-Roosevelt Hospital Center.
Advertisement
Advertisement
Related to this article
At week 112, at least 72% of patients on icotrokinra held PASI 90 and at least 44% held PASI 100, with no new safety signals reported.
Raj Chovatiya, MD, PhD, MSCI, discusses the FDA approval of remibrutinib for symptomatic dermographism and what an on-label option means for patients.
By week 36, combination therapy altered 482 proteins and 467 genes vs 140 and 16 with ixekizumab alone in exploratory TOGETHER-PsO data.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
The supplemental New Drug Application seeks to expand the use of Ameluz with red light photodynamic therapy beyond the face and scalp to actinic keratoses on the extremities, neck, and trunk.
The 4-day CME meeting in Las Vegas offers up to 24.25 credits and sessions on inflammatory skin disease, skin cancer, pediatric dermatology, aesthetics, and more.
A biopsy-based analysis from the JADE MOA trial presented at EADV 2026 found reductions in pathogenic skin-resident memory T cells alongside restoration of epidermal barrier integrity.
Advertisement
Advertisement
Trending on Dermatology Times
1
Upadacitinib Shows Broader Inflammatory Effects and Earlier Skin Barrier Restoration Than Dupilumab in Atopic Dermatitis
2
Ixekizumab Plus Tirzepatide Shifts Biomarkers in Psoriasis with Obesity
3
FDA Approves Remibrutinib for Symptomatic Dermographism
4
Augmented Intelligence in Skin Cancer Detection and Prognosis
5